TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04453189
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will receive famotidine in fasted condition on Day 1 in assigned treatment sequence.
Study: NCT02955810
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02955810
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02955810
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04440007
Drug: Abivertinib
Normalized name: Abivertinib
DrugBank: Abivertinib (DB15327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
Study: NCT04275388
Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
Study: NCT03467386
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given CIV
Study: NCT03683251
Drug: PDS Implant with Ranibizumab 100 mg/mL
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will be administered as per the schedule described in individual arm
Study: NCT03924986
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenously (IV) once every 3 weeks (Q3W)
Study: NCT03924986
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gram per square meter of body surface area (g/m\^2) on Day 1 and day 8 of each cycle, administered as an IV infusion within 30 minutes, for 4 to 6 cycles
Study: NCT03924986
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 milligrams per square meter of body surface area (mg/m\^2) on Day 1 of each cycle, administered as an IV infusion for over 4 hours if possible or with proper infusion time based on local clinical guidelines or clinical practice and according to the treating physician's clinical judgment, for 4 to 6 cycles.
Study: NCT01428661
Drug: tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg once daily
Study: NCT03781934
Drug: MIV-818 (fostroxacitabine bralpamide) + pembrolizumab
Normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MIV-818 - oral capsules; pembrolizumab - IV
Study: NCT03781934
Drug: MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Normalized name: Troxacitabine nucleotide prodrug miv-818
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MIV-818 - oral capsules; lenvatinib - oral capsules
Study: NCT03105102
Drug: Placebo for Risankizumab SC
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for Risankizumab SC Subcutaneous (SC) Injection
Study: NCT03105102
Drug: Risankizumab IV
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab IV Intravenous (IV) infusion
Study: NCT03105102
Drug: Placebo for Risankizumab IV
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for Risankizumab IV Intravenous (IV) infusion
Study: NCT03105102
Drug: Risankizumab SC
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Risankizumab SC Subcutaneous (SC) injection
Study: NCT03105102
Drug: Risankizumab On-Body Injector (OBI)
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous (SC) injection; on-body injector (OBI)
Study: NCT00921765
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline single bolus dose followed by saline single bolus dose iv
Study: NCT00921765
Drug: Saline + Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
Study: NCT02736500
Drug: 28 GBq 177Lu-DOTATATE
Normalized name: 177Lu-dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
Study: NCT02736500
Drug: 22 GBq 177Lu-DOTATATE
Normalized name: 177Lu-dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
Study: NCT00921765
Drug: Naloxone + Placebo
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
Study: NCT00921765
Drug: Naloxone + Ketamine
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
Study: NCT03526185
Drug: Tumor Infiltrating Lymphocytes
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
Study: NCT03526185
Drug: Nivolumab and Ipilimumab
Normalized name: nivolumab and relatlimab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: • Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
Study: NCT04948385
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
Study: NCT00597727
Drug: Peanut SLIT
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
Study: NCT01073059
Drug: Valproic acid and Ertapenem
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00877214
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
Study: NCT00877214
Drug: Rituximab / observation
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
Study: NCT04200781
Drug: Granules of Shengdi Dahuang Decoction
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
Study: NCT00666718
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient glucose-level dependent, injection, once daily in the evening, 24 weeks
Study: NCT00666718
Drug: Insulin Lispro Protamine Suspension (ILPS)
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patient glucose-level dependent, injection, once daily in the evening, 24 weeks
Study: NCT00666718
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous injections prior to meals, 24 weeks
Study: NCT00246441
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
Study: NCT00003119
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003119
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01165736
Drug: PF-05186462
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous infusion of 100 microgram
Study: NCT01165736
Drug: PF-05186462
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration of 100 microgram
Study: NCT01165736
Drug: PF-05089771
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous infusion of 100 microgram of PF-05089771
Study: NCT01165736
Drug: PF-05089771
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration of 100 microgram PF-05089771
Study: NCT01165736
Drug: PF-05150122
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous administration of 100 microgram PF-05150122
Study: NCT01165736
Drug: PF-05150122
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration of 100 microgram PF-05150122
Study: NCT01165736
Drug: PF-05241328
Normalized name: PF-05241328
DrugBank: PF-05241328 (DB15124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous infusion of 100 microgram PF-05241328
Study: NCT01165736
Drug: PF-05241328
Normalized name: PF-05241328
DrugBank: PF-05241328 (DB15124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration 100 microgram PF-05241328
Study: NCT03491709
Drug: anti-EGFR monoclonal antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
Study: NCT03491709
Drug: Cetuximab injection
Normalized name: cetuximab Injection
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab injection
Study: NCT04711668
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative ketamine bolus and infusion
Study: NCT04711668
Drug: Lidocain
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative lidocain bolus and infusion
Study: NCT04711668
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraoperative saline bolus and infusion
Study: NCT00960310
Drug: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
Normalized name: bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00960310
Drug: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
Normalized name: bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01578343
Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation
Study: NCT01368757
Drug: Revlimid
Normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen.
Study: NCT01898117
Drug: Carbo/cyclo
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01898117
Drug: Carbo/cyclo + atezolizumab
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01898117
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01898117
Drug: Paclitaxel + Atezolizumab
Normalized name: Atezolizumab
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00219544
Drug: Pregabalin (Lyrica)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin 150mg/day (75mg BID)
Study: NCT00963599
Drug: Comparator: montelukast/loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
Study: NCT00963599
Drug: Comparator: montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast 10 mg tablet taken once daily at bed time for 2 weeks
Study: NCT00963599
Drug: Comparator: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loratadine 10 mg tablet taken once daily at bed time for 2 weeks
Study: NCT04658199
Drug: UCB0107 (bepranemab)
Normalized name: Immunoglobulin g4 (226-proline), anti-(human tau protein) (human-rattus norvegicus monoclonal ucb0107 .gamma.4-chain), disulfide with human-rattus norvegicus monoclonal ucb0107 .kappa.-chain, dimer
DrugBank: Bepranemab (DB17945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous
Study: NCT02460133
Drug: Paritaprevir
Normalized name: Paritaprevir
DrugBank: Paritaprevir (DB09297)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02460133
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02460133
Drug: Dasabuvir
Normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02460133
Drug: Ombitasvir
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02460133
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
Study: NCT00390793
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or IT
Study: NCT00390793
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00390793
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT01958593
Drug: Midomafetamine
Normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
Study: NCT00390793
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00390793
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02858076
Drug: 2-mg Intravitreous Aflibercept Injection
Normalized name: aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
Study: NCT00219544
Drug: Pregabalin (Lyrica)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin 300 mg/day (150mg BID)
Study: NCT00219544
Drug: Pregabalin (Lyrica)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin 600/day (300mg BID)
Study: NCT00410592
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410592
Drug: Pantoprazole 40mg
Normalized name: pantoprazole 40 MG
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410592
Drug: Lansoprazole 30mg
Normalized name: LANSOPRAZOLE 30MG CAP,SA
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04199598
Drug: Abediterol (2.4 μg)
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
Study: NCT04199598
Drug: Abediterol (4.8 μg)
Normalized name: patiromer
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
Study: NCT04199598
Drug: Abediterol (2.4 μg)
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
Study: NCT00203957
Drug: Istradefylline
Normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
Study: NCT04199598
Drug: Abediterol (2.5 μg)
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg (nominal dose) abediterol via DPI, reference
Study: NCT01958112
Drug: GSK1120212 (trametinib)
Normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib dose is 1.5 mg orally once per day
Study: NCT02376283
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02376283
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02376283
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00056498
Drug: Risperdal
Normalized name: Risperdal
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperdal 4 mg per day for 16 weeks
Study: NCT00814801
Drug: Galantamine 16 mg/day
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
Study: NCT00814801
Drug: Galantamine 24 mg/day
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
Study: NCT01141049
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
Study: NCT03706222
Drug: elbasvir/grazoprevir
Normalized name: ELBASVIR/GRAZOPREVIR
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
Study: NCT04238676
Drug: PP353
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active administered by intradiscal injection
Study: NCT00190684
Drug: atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
Study: NCT03496207
Drug: Sotatercept
Normalized name: Sotatercept
DrugBank: Sotatercept (DB12118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.
Study: NCT00839007
Drug: CD-NP
Normalized name: CD-NP
DrugBank: Cenderitide (DB11777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of CD-NP at one of up to 6 doses or placebo
Study: NCT01925378
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration.